

Eleven Biotherapeutics Investor Relations Department 245 First Street, Suite 1800 Cambridge, MA 02142 United States

Visit IR website ☐ Sign-up for email alerts ☐ ☐

NASDAQ: EBIO	
Last Trade:	1.11
Trade Time:	4:00 PM ET August 18, 2017
Change:	-0.01 🖶 (0.893%)
Day Range	1.00 - 1.14
52-Week Range	1.00 - 5.40
Volume	490,916

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Eleven Biotherapeutics, Inc. is a late clinicalstage company advancing a broad pipeline of novel anticancer agents based on our Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine targeting antibody fragments with cytoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.

We have designed TPTs with the potential to offer:

- Multiple advantages in treating cancer over traditional antibody drug conjugates.
- Effective tumor targeting with cancer cell -killing... (more)

Stock Performance



Press Releases [View all]

August 14, 2017

<u>Eleven Biotherapeutics Reports Second</u> <u>Quarter 2017 Financial Results</u>

August 7, 2017

Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017

August 3, 2017

Eleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference

June 12, 2017

Eleven Biotherapeutics to Present at 2017 Marcum MicroCap Conference

June 6, 2017

Eleven Biotherapeutics to Collaborate with
AstraZeneca and the National Cancer
Institute on Development of ViciniumTM in
Combination with Durvalumab for the
Treatment of Non-Muscle Invasive Bladder
Cancer

Financials [View all]

Second Quarter Financial Results

March 24, 2017 Annual Report (10-K)

April 7, 2017
Proxy Statement (DEF 14A)

August 14, 2017
Quarterly Report (10-Q)

May 4, 2017 Quarterly Report (10-Q)

November 14, 2016
Quarterly Report (10-Q)